Pitolisant, sold under the brand name Wakix among others, is a medication for the treatment of excessive daytime sleepiness in adults with narcolepsy. It is a histamine 3 (H3) receptor antagonist/inverse agonist. It represents the first commercially available medication in its class. Pitolisant enhances the activity of histaminergic neurons in the brain that function to improve a person's wakefuln… WebOct 28, 2024 · Wakix (pitolisant) is a histamine-3 (H₃) receptor antagonist/inverse agonist for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adult patients with narcolepsy. Wakix is taken once daily in the morning upon wakening. IMPORTANT SAFETY INFORMATION Wakix should not be used in patients with severe liver disease.
A Phase 3 Study to Assess the Safety and Efficacy of Pitolisant in ...
WebJan 24, 2024 · 2024年1月24日,临床阶段生物制药公司Aculys Pharma, Inc.宣布在日本启动Pitolisant治疗与阻塞性睡眠呼吸暂停综合征(OSAS)相关的白天过度嗜睡(EDS)患者的3期临床研究。该试验是一项多中心、随机、双盲、安慰剂对照、平行组研究和随后的多中心、开放标签、长期扩展研究(第二部分),以评估在日本 ... WebMay 27, 2024 · Cardiovascular diseases are comorbid in patients with narcolepsy. Cardiovascular adverse effects are of concern with narcolepsy medications because of this comorbidity and most patients require lifelong pharmacotherapy. Pitolisant, a selective histamine 3 (H 3 )-receptor antagonist/inverse agonist, increases histamine transmission … michael barrymore house today
Wakix oral: Uses, Side Effects, Interactions, Pictures ... - WebMD
WebMedical uses. Pitolisant (Wakix) is used in adults for the treatment of narcolepsy. Narcolepsy is a chronic sleep disorder that causes overwhelming daytime drowsiness. Pitolisant (Ozawade) is indicated to improve alertness and reduce excessive daytime sleepiness in adults with obstructive sleep apnea.. Side effects. The most common side … WebPitolisant, a selective histamine H3 receptor inverse agonist, has been approved in Europe and USA for adults with narcolepsy with or without cataplexy, with a favourable safety profile. This phase 3 study aimed to assess the safety and efficacy of pitolisant in children with narcolepsy with or without cataplexy. WebCitation 77–79 Further, gender-specific medication is very important, since the effectiveness of steroidal contraceptives (sensitive CYP3A4 substrates) may be affected by the use of pitolisant and modafinil. Hence, gender-specific future clinical trials are warranted to understand the differential impact of narcolepsy treatment. michael barrymore house roydon